Ohio State spinoff raises $59M to tackle deadly disease with no other treatment

Entrada Therapeutics

An Ohio State University spinoff developing a treatment for a deadly mitochondrial disease launched Tuesday in Boston with a $59 million round of venture capital investment.

Entrada Therapeutics is using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in the power center of a cell.

Click here to read the complete article, and see related story at WOSU.

Story excerpt provided by Columbus Business First.

Written by Allison DeAngelis.

Originally published December 19, 2018.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: